Cargando…
Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience
The current standard first line therapy for fit patients with B-CLL/SLL is based on combination of fludarabine-cyclophosphamide and rituximab. However, elderly patients or patients with comorbidities poorly tolerate purine analogue-based chemotherapy and they are often treated with Chlorambucil (Chl...
Autores principales: | Laurenti, Luca, Vannata, Barbara, Innocenti, Idanna, Autore, Francesco, Santini, Francesco, Piccirillo, Nicola, Za, Tommaso, Bellesi, Silvia, Marietti, Sara, Sica, Simona, Efremov, Dimitar G., Leone, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647714/ https://www.ncbi.nlm.nih.gov/pubmed/23667729 http://dx.doi.org/10.4084/MJHID.2013.031 |
Ejemplares similares
-
The Use of Monoclonal Antibodies in the Treatment of Autoimmune Complications of Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2013) -
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
por: Autore, Francesco, et al.
Publicado: (2020) -
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016) -
Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review
por: Fresa, Alberto, et al.
Publicado: (2021) -
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience
por: Autore, Francesco, et al.
Publicado: (2021)